Falsification and Pharmacovigilance: What Do Patients Get to See and What Should They Do with It?




Download Your Copy

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.

 Are we really ‘enabling patients to act appropriately’?

The ‘Falsified medicines directive’ (2011/62/EU) and the ‘Pharmacovigilance regulation’ (No 1235/2010) will influence some of the information that patients receive about medicines. In both the directive and the regulation, several forms of visual communication are mentioned. Dr Karel van der Waarde thinks that it is unlikely that a modification in the visual presentation has much influence on these actions of people. In this discussion piece Dr Karel van der Waarde explores the impact of the latest falsification and pharmacovigilance regulation on pharmaceutical packaging.

By Dr Karel van der Waarde, Pharmaceuticals Consultant and Graphic Design Researcher Independent

Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue reading this story

Learn More   Existing Users